The trial showed that dose response was not observed, yet a 30% relative risk reduction was seen in symptomatic ischaemic strokes with milvexian.
In rheumatic heart disease-associated AF patients, VKAs therapy was non-inferior to rivaroxaban for a composite of cardiovascular events or death rates.
Multisystemic inflammatory syndrome can appear in children and adolescents as a consequence of SARS-CoV-2 infection.
Surgery planning, education or even communication: Virtual and augmented reality give room to many applications in patient-physician interactions.
A prospective study showed that the medication did not reduce events, including non-fatal MI, non-fatal stroke, or cardiovascular death, in patients with IHD.
Treating severe hypertriglyceridaemia patients with subcutaneous pegozafermin significantly reduced triglycerides across all study dose groups.
SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisation for heart failure across HFpEF/HFmrEF patient subgroups.
In severe ischaemic left ventricular systolic dysfunction patients, PCI did not reduce the composite incidence of all cause death or hospitalisation for heart failure.
The BOX trial shows that outcomes of comatose patients after an OHCA are not affected by shifting targets of oxygenation or blood-pressure.
A high-dose vaccination (60 μg of haemagglutinin antigen) in older adults reduced death risk by 49% and hospitalisation by 64%, compared with standard-dose vaccination.
PPIs should work against gastrointestinal complaints, but some patients need them permanently. Researchers have set therapy guidelines for this.
Adding acetazolamide to loop diuretics in ADHF patients with volume overload improved rates of successful decongestion within 3 days.
Results point to a screening target age below 70 years, for a substantial reduction of combined endpoints of death, stroke, or myocardial infarction.
The TIME trial reported that taking antihypertensives mornings or evenings, provides identical protection against heart attack, stroke, or vascular death.
After blinded review of initial LVEF assessment, cardiologists were less likely to substantially change final reports with initial AI than sonographer assessment.
The 'polypill' dose of aspirin, ramipril, and atorvastatin prevents secondary CV events in people ≥65 years old who previously had myocardial infarction.
Focused ultrasound waves can be used to destroy tissue with millimetre precision. The innovative technology is being tested in the 'HOPE4LIVER' study.
Dapagliflozin reduced cardiovascular death risk or worsening heart failure in patients with mildly reduced and preserved ejection fraction.
Trial results show no evidence that neprilysin inhibition raised cognitive impairment risk due to brain amyloid-β accumulation, for HFmrEF/HFpEF patients.
mRNA vaccines should induce viral proteins directly in the body and stimulate the immune system to produce broadly neutralising antibodies against HIV.